Halozyme Therapeutics | HALO - Pre Tax Profit

Stock Price
69.53
Daily Change
0.31 0.45%
Monthly
-4.53%
Yearly
17.55%
Q1 Forecast
68.78

Halozyme Therapeutics reported $218.96M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -8.12M 5.34M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Baxter International USD 121M 12M Sep/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
MannKind USD -20.93M 28.71M Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Pfizer USD 3.33B 290M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024